📱 FDA Authorizes CT-132: First Prescription Digital Therapeutic for Episodic Migraine Prevention

Click Therapeutics has received FDA marketing authorization for CT-132, the first prescription digital therapeutic (PDT) approved for the preventive treatment of episodic migraine in adults. Delivered via a smartphone app, CT-132 offers a non-pharmacologic, adjunctive option to existing migraine treatments.

​

Key Highlights:

Regulatory Milestone: Approved through the FDA’s De Novo pathway, CT-132 is the first PDT authorized specifically for migraine prevention.

​

Clinical Efficacy: In a large Phase 3 trial, CT-132 users experienced a significant reduction in monthly migraine days (–3.04 days) compared to sham (–0.9 days).

​

Quality of Life Improvements: Participants reported improvements in migraine-related quality of life and disability as early as week 4, sustained through week 12.

​

High Adherence and Safety: The 12-week program achieved nearly 100% median task completion, with no treatment-related adverse events.

​

Mechanism of Action: CT-132 integrates cognitive behavioral therapy and other validated techniques to influence the brain networks involved in migraine development.

1. 📱 Digital Therapeutics (DTx) in Neurology: Definition, Scope, and Regulation

Digital therapeutics are software-based, clinically validated interventions delivered via apps or devices. Unlike wellness apps, PDTs like CT-132 undergo rigorous clinical trials and FDA review, offering evidence-based adjuncts for neurologic disorders including migraine, insomnia, and MS-related fatigue.

2. 🧠 Migraine Management Apps: From Diaries to Interventions

Beyond tracking, apps now offer preventive behavioral therapies including CBT, mindfulness, and biofeedback for migraine. Key examples include CT-132, Migraine Buddy, and TheraNow. Neurologists benefit from understanding which tools are regulated, effective, and reimbursable.

3. 🔬 Evidence for Behavioral Interventions in Migraine

Studies have shown that CBT, relaxation techniques, and mindfulness-based stress reduction improve migraine frequency and severity. CT-132 digitizes and automates these techniques — providing a structured alternative when in-person therapy is inaccessible.

4. 🌐 DTx for Other Neurological Conditions

Apps are being developed or FDA-authorized for:

• MS-related fatigue (e.g., MS Energize)
• Insomnia (e.g., Somryst)
• ADHD (e.g., EndeavorRx)
  These tools often target neurocognitive symptoms or quality-of-life impairments, and neurologists should be aware of their mechanisms and clinical trial backing.

5. 🔒 Challenges in Integrating Digital Tools into Neurology Practice

Adoption of DTx faces hurdles: clinician awareness, workflow integration, insurance coverage, and data interpretation. Understanding these barriers helps neurologists advocate for interoperable, reimbursable tools that align with clinical standards and patient needs.

📚 References

1. Morley, K. C., et al. (2025). Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial.Neuropsychopharmacology.
   ​https://www.nature.com/articles/s41386-025-02097-0​
2. Reijnders, J. S. A. M., et al. (2008). A systematic review of prevalence studies of depression in Parkinson’s disease.Movement Disorders, 23(2), 183–189.
3. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future.Neuropsychopharmacology, 42(11), 2105–2113.
4. Griffiths, R. R., et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Journal of Psychopharmacology, 30(12), 1181–1197.
5. Daws, R. E., et al. (2022). Increased neuroplasticity after psilocybin therapy for depression.Nature Medicine, 28(5), 844–851.
6. Preller, K. H., & Vollenweider, F. X. (2016). Phenomenology, structure, and dynamic of psychedelic states. In Behavioral Neurobiology of Psychedelic Drugs (pp. 221–256). Springer.
7. Tesch, J., et al. (2023). Safety of psychedelics in patients with neurodegenerative or psychiatric comorbidities: a narrative review.Frontiers in Pharmacology, 14, 1130402.
8. Aarsland, D., et al. (2021). Cognitive decline in Parkinson disease.Nature Reviews Neurology, 17(2), 65–80.
9. Friedman, J. H. (2012). Psychiatric issues in Parkinson’s disease.Neurologic Clinics, 30(3), 789–808.
10. Feldman, R., et al. (2021). Mind-body interventions for neurodegenerative diseases: A review.Frontiers in Aging Neuroscience, 13, 682923.